Clinical Trials Browser

Tertiary Lymphoid Structures, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

ADJUNCT

OZM-034

MK-5890-003

CaptAin

IMpALA

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

EMPIRE

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

TNBC

Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage

Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

A Feasibility and Acceptability Pilot Study Evaluating a Patient-Specific Targeted Intervention Using Patient Navigators or Routine Clinical Care

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

PELICAN

Non-Viral TCR Gene Therapy

Evaluation of Hydroxychloroquine to Prevent CIPN

Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Patients

INTRUSION

Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass

Chemo-free BRCA-targeted Neoadjuvant Strategy

Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy

Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response

HER2-Signal

AdvanTIG-211

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy

Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial

Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

MATILDA

Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy

Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

MARGARET

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

DoT-FMI

EURO-DIGNITY

NeraBrain

VERU-111

Breast 51

APBI

PANDoRA

Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer

ABLATIVE-2

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer